Dexcom director granted 1,630 restricted stock units

Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.

Dexcom Inc. director Albert Frederick Osterloh IV received an equity grant of 1,630 restricted stock units (RSUs) of Dexcom common stock on May 28, 2026. The award was granted at no cash cost as part of compensation, not through an open-market purchase.

All 1,630 RSUs will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this grant, Osterloh holds 8,691 unvested RSUs in total, including 7,061 RSUs granted on February 26, 2026 that are scheduled to vest through February 26, 2029.

Insider Trade Summary

Grant/Award: 1,630 shares

Grant/Award 1 txn

Insider Osterloh Albert Frederick IV

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,630	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,691 shares (Direct)

Footnotes (2)

1. F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
2. F2. Included in this number are 8,691 unvested restricted stock units, 1,630 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,061 of which were granted on February 26, 2026 and shall vest through February 26, 2029.

Key Figures

RSUs granted: 1,630 RSUs Grant price per share: $0.00 per share Unvested RSUs after grant: 8,691 RSUs +2 more

5 metrics

RSUs granted 1,630 RSUs Equity award granted May 28, 2026

Grant price per share $0.00 per share RSU award classified as compensation grant

Unvested RSUs after grant 8,691 RSUs Total unvested restricted stock units held after May 28, 2026

Prior RSU grant 7,061 RSUs Granted February 26, 2026; vest through February 26, 2029

Vesting trigger Earlier of 1-year from grant or 2027 meeting Vesting condition for 1,630 May 28, 2026 RSUs

Key Terms

restricted stock unit, RSU Award, Annual Meeting of Stockholders, contingent right

4 terms

restricted stock unit financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU Award financial

"The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest"

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

contingent right financial

"that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) report for Albert Frederick Osterloh IV?

Dexcom reported that director Albert Frederick Osterloh IV received a grant of 1,630 restricted stock units of Dexcom common stock on May 28, 2026. The RSUs were awarded at no cash cost as equity compensation, not as an open-market stock purchase or sale.

When do the newly granted Dexcom (DXCM) RSUs to Albert Osterloh vest?

The 1,630 newly granted RSUs will vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or the date of Dexcom’s 2027 Annual Meeting of Stockholders. Vesting timing is therefore tied to either a fixed date or that shareholder meeting.

How many unvested Dexcom (DXCM) RSUs does Albert Osterloh hold after this Form 4?

Following the May 28, 2026 grant, Albert Osterloh holds a total of 8,691 unvested Dexcom restricted stock units. This includes 1,630 RSUs from the new grant and 7,061 RSUs granted on February 26, 2026 that are scheduled to vest in tranches through February 26, 2029.

Is Albert Osterloh’s Dexcom (DXCM) Form 4 transaction a stock purchase or compensation grant?

The Form 4 reflects a compensation-related grant, not a market purchase. Albert Osterloh received 1,630 restricted stock units at a stated price of $0.00 per share, indicating an equity award classified as a grant, award, or other acquisition under the Form 4 transaction code A.

What does each Dexcom (DXCM) restricted stock unit represent in Osterloh’s grant?

Each restricted stock unit in Albert Osterloh’s award represents a contingent right to receive one share of Dexcom common stock upon settlement. The units are subject to vesting conditions tied to time and the 2027 Annual Meeting, and they convert into shares only when those conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Osterloh Albert Frederick IV

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		1,630(1)	A	$0	8,691(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

2. Included in this number are 8,691 unvested restricted stock units, 1,630 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,061 of which were granted on February 26, 2026 and shall vest through February 26, 2029.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Albert Frederick (Rick) Osterloh IV	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)